drugset / Trial / NCT05629234
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
NaSequentialOpen-labelTreatment
Summary
The rationale of the ROSY-T study is to continue to provide study treatment for patients who have participated in a parent study with osimertinib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.
Timeline
- Start
- 2023-05-08
- Primary completion
- 2027-02-22
- Completion
- 2027-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osimertinib | Small molecule | 40 mg | Oral |
| Subject | Osimertinib | Small molecule | 240 mg | Oral |